"Northwestern Medicine scientists have discovered a potent immunotherapy approach for treating meningiomas, the most common type of primary brain tumor, according to a recent study published in Nature Communications. More than 39,000 Americans are diagnosed with meningioma each year, according to the National Brain Tumor Society. The tumor originates from cells in the meninges, a fibrous membrane that covers and protects the brain and spinal cord."
"From this analysis, the scientists discovered that the STING pathway - which has been shown to play in a role in cancer by supporting anti-tumor immunity - is expressed both within the meningioma tumor cells and in the immune cells circulating within the tumor microenvironment. "STING is actually expressed in the meningioma tumor cells themselves and not just in the infiltrative immune populations, which is unique from other types of brain tumors such as gliomas," Youngblood said."
Meningiomas arise from cells in the meninges and affect more than 39,000 Americans annually. Many meningiomas respond to surgery and radiation, but advanced or aggressive tumors become therapy-resistant and can recur with higher morbidity or mortality. Single-cell RNA sequencing data from 22 patients revealed expression of the STING pathway within both meningioma tumor cells and infiltrating immune cells in the tumor microenvironment. STING expression in tumor cells distinguishes meningiomas from other brain tumors such as gliomas. Researchers administered a STING agonist, 8803, to human meningioma tumor samples to activate the pathway and target tumor and immune populations.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]